{"component": "definition", "props": {"groups": [{"size": 50, "snippet_links": [{"key": "section-341", "type": "clause", "offset": [36, 49]}], "samples": [{"hash": "ixNwZX1Bmqj", "uri": "/contracts/ixNwZX1Bmqj#development-committee", "label": "License and Development Agreement (Novadel Pharma Inc)", "score": 18.0, "published": true}, {"hash": "hpocfi8s7s3", "uri": "/contracts/hpocfi8s7s3#development-committee", "label": "License and Development Agreement (Hana Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "hIa6pmXBWR9", "uri": "/contracts/hIa6pmXBWR9#development-committee", "label": "License and Development Agreement (Manhattan Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "shall have the meaning set forth in Section 3.4.1.", "hash": "c7f20d15c843781d06ae9d51793f1655", "id": 1}, {"size": 25, "snippet_links": [{"key": "article-3", "type": "definition", "offset": [29, 38]}, {"key": "amended-and-restated-research-and-development-agreement", "type": "definition", "offset": [46, 101]}], "samples": [{"hash": "fHpZ0nWKdJl", "uri": "/contracts/fHpZ0nWKdJl#development-committee", "label": "Purchase Option Agreement (Alexza Pharmaceuticals Inc.)", "score": 25.8432579041, "published": true}, {"hash": "fZrtfvQpEFb", "uri": "/contracts/fZrtfvQpEFb#development-committee", "label": "Warrant Purchase Agreement (Exelixis Inc)", "score": 21.591375351, "published": true}, {"hash": "fjFlkkVu3vE", "uri": "/contracts/fjFlkkVu3vE#development-committee", "label": "Purchase Option Agreement (Dynavax Technologies Corp)", "score": 21.2026004791, "published": true}], "snippet": "has the meaning set forth in Article 3 of the Amended and Restated Research and Development Agreement.", "hash": "a9d1f17b063a45ff4f5f8110d199771f", "id": 2}, {"size": 13, "snippet_links": [], "samples": [{"hash": "1pgJyXuPhyy", "uri": "/contracts/1pgJyXuPhyy#development-committee", "label": "Co Development and Co Commercialization Agreement", "score": 31.3408622742, "published": true}, {"hash": "fvMI8zKYVhy", "uri": "/contracts/fvMI8zKYVhy#development-committee", "label": "Co Development and Co Commercialization Agreement (Alexion Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "lEaqJi4ldYk", "uri": "/contracts/lEaqJi4ldYk#development-committee", "label": "Co Development and Co Commercialization Agreement (Alexion Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "has the meaning set forth in Section 2.1(b).", "hash": "81b3cece4ce9d41609707694c7ab11f8", "id": 3}, {"size": 11, "snippet_links": [{"key": "building-permits", "type": "clause", "offset": [10, 26]}, {"key": "property-development", "type": "definition", "offset": [31, 51]}, {"key": "by-the-board", "type": "clause", "offset": [72, 84]}, {"key": "review-and-approve", "type": "clause", "offset": [88, 106]}], "samples": [{"hash": "9jU3ZUqmoKP", "uri": "https://lakecorp.com/wp-content/uploads/documents/loc-rules-regulations-updated-07-16-24.pdf", "label": "lakecorp.com", "score": 17.1107769012, "published": false}, {"hash": "cDW54mCc9FF", "uri": "https://lakecorp.com/wp-content/uploads/documents/loc-rules-regulations-updated-03-05-24.pdf", "label": "lakecorp.com", "score": 10.0869264603, "published": false}, {"hash": "ec8MdCAzeqG", "uri": "https://lakecorp.com/wp-content/uploads/documents/loc-rules-regulations-2-updated-02-06-24.pdf", "label": "lakecorp.com", "score": 10.0485963821, "published": false}], "snippet": "means the Building Permits and Property Development Committee appointed by the Board to review and approve, condition, or deny Requests.", "hash": "ab1b84173cf093ad2e385abf7ff3549d", "id": 4}, {"size": 7, "snippet_links": [{"key": "section-22", "type": "clause", "offset": [14, 25]}], "samples": [{"hash": "leIjkUHKome", "uri": "/contracts/leIjkUHKome#development-committee", "label": "Development and License Agreement (Insulet Corp)", "score": 18.0, "published": true}, {"hash": "hImMCDOQE2O", "uri": "/contracts/hImMCDOQE2O#development-committee", "label": "Gaming Development Consulting Agreement (Lakes Entertainment Inc)", "score": 18.0, "published": true}, {"hash": "h2UGlo5oJSv", "uri": "/contracts/h2UGlo5oJSv#development-committee", "label": "Gaming Development Consulting Agreement (Lakes Entertainment Inc)", "score": 18.0, "published": true}], "snippet": "is defined in Section 2.2.", "hash": "4ee7eda26dfe6b7fc079c925b48b24a1", "id": 5}, {"size": 6, "snippet_links": [{"key": "the-committee", "type": "clause", "offset": [6, 19]}, {"key": "article-ii", "type": "definition", "offset": [53, 63]}, {"key": "this-agreement", "type": "clause", "offset": [67, 81]}], "samples": [{"hash": "dK18dtgUNbA", "uri": "/contracts/dK18dtgUNbA#development-committee", "label": "Development Collaboration and License Agreement (Genentech Inc)", "score": 18.0, "published": true}, {"hash": "TY6mD2lMhe", "uri": "/contracts/TY6mD2lMhe#development-committee", "label": "Development Collaboration and License Agreement (Cytotherapeutics Inc/De)", "score": 18.0, "published": true}, {"hash": "2PlV8Lh4mPy", "uri": "/contracts/2PlV8Lh4mPy#development-committee", "label": "Development Collaboration and License Agreement (Cytotherapeutics Inc/De)", "score": 18.0, "published": true}], "snippet": "means the committee organized and acting pursuant to Article II of this Agreement.", "hash": "6c7313bd45d7d55a1eee499316981293", "id": 6}, {"size": 6, "snippet_links": [{"key": "the-committee", "type": "clause", "offset": [6, 19]}, {"key": "section-32", "type": "definition", "offset": [33, 44]}], "samples": [{"hash": "hikclAXqIkA", "uri": "/contracts/hikclAXqIkA#development-committee", "label": "License Agreement (Indevus Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "cFkln2FJPI6", "uri": "/contracts/cFkln2FJPI6#development-committee", "label": "Exclusive Development and Commercialization Agreement (Molichem Medicines Inc)", "score": 18.0, "published": true}, {"hash": "5NKp3p8cBa0", "uri": "/contracts/5NKp3p8cBa0#development-committee", "label": "Exclusive Development and Commercialization Agreement (Molichem Medicines Inc)", "score": 18.0, "published": true}], "snippet": "means the committee described in Section 3.2.", "hash": "6256c6484f9b338f116cf03a3d915bfd", "id": 7}, {"size": 6, "snippet_links": [{"key": "committee-established", "type": "clause", "offset": [18, 39]}, {"key": "pursuant-to-section", "type": "definition", "offset": [40, 59]}], "samples": [{"hash": "emeRKDrqikU", "uri": "/contracts/emeRKDrqikU#development-committee", "label": "Focused Collaboration Agreement (Regeneron Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "3uu1Ht3AeOi", "uri": "https://investor.regeneron.com/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.965092659, "published": false}, {"hash": "bNv3NN3IRdM", "uri": "https://investor.regeneron.com/index.php/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.3312797546, "published": false}], "snippet": "or \"DC\" means the committee established pursuant to Section 2.5(c).", "hash": "789fb4b4a85b11c61e5ccab63dd495c9", "id": 8}, {"size": 5, "snippet_links": [{"key": "the-joint-committee", "type": "definition", "offset": [6, 25]}, {"key": "representatives-of", "type": "clause", "offset": [38, 56]}, {"key": "section-62", "type": "clause", "offset": [82, 93]}, {"key": "this-agreement", "type": "clause", "offset": [97, 111]}], "samples": [{"hash": "jaJZXYeuxuU", "uri": "/contracts/jaJZXYeuxuU#development-committee", "label": "License Agreement (Transkaryotic Therapies Inc)", "score": 18.0, "published": true}, {"hash": "jMT0okhke7w", "uri": "/contracts/jMT0okhke7w#development-committee", "label": "License Agreement (Transkaryotic Therapies Inc)", "score": 18.0, "published": true}, {"hash": "9lrBijqAsoZ", "uri": "/contracts/9lrBijqAsoZ#development-committee", "label": "License Agreement (Transkaryotic Therapies Inc)", "score": 18.0, "published": true}], "snippet": "means the joint committee composed of representatives of TKT and MMD described in Section 6.2 of this Agreement.", "hash": "e697fb44a81a0d5c1ecfc65c6b4ec44c", "id": 9}, {"size": 5, "snippet_links": [{"key": "section-21", "type": "clause", "offset": [39, 50]}], "samples": [{"hash": "4rORXaJ9KTj", "uri": "/contracts/4rORXaJ9KTj#development-committee", "label": "Gvax Agreement (Cell Genesys Inc)", "score": 21.0, "published": true}, {"hash": "j4NI4iivDPr", "uri": "/contracts/j4NI4iivDPr#development-committee", "label": "Gvax Agreement (Cell Genesys Inc)", "score": 18.0, "published": true}], "snippet": "shall have the meaning as set forth in Section 2.1 below.", "hash": "9de38e592a4c1b7715b3fca66febf0b3", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIeZGV2ZWxvcG1lbnQtY29tbWl0dGVlIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 251, "title": "Development Committee", "snippet": "shall have the meaning set forth in Section 3.4.1.", "id": "development-committee", "examples": ["At the first quorate meeting of the Board of Managers called in accordance with Section 3.02(b), or, subject to Section 3.02(d), pursuant to a written consent, the Board of Managers shall (i) vote to approve the adoption of the Pre-FID Budget and (ii) establish the <strong>Development Committee</strong>.", "Unless otherwise agreed by each Member with a Common Percentage of at least 22.5%, the <strong>Development Committee</strong> shall meet at least once every calendar month."], "related": [["joint-development-committee", "Joint Development Committee", "Joint <strong>Development Committee</strong>"], ["steering-committee", "Steering Committee", "Steering Committee"], ["project-steering-committee", "Project Steering Committee", "Project Steering Committee"], ["research-committee", "Research Committee", "Research Committee"], ["joint-steering-committee", "Joint Steering Committee", "Joint Steering Committee"]], "related_snippets": [], "updated": "2026-03-29T04:25:46+00:00"}, "json": true, "cursor": ""}}